Core Viewpoint - Stagwell (STGW) has shown an 8.1% increase in stock price over the past four weeks, with a mean price target of $7.73 indicating a potential upside of 37.5% from the current price of $5.62 [1] Price Targets and Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $1.28, where the lowest estimate is $6.00 (6.8% increase) and the highest is $9.00 (60.1% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement, which can be a starting point for further research [9] Analyst Sentiment and Earnings Estimates - Analysts have shown growing optimism about STGW's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 1.6% over the past month, with one estimate going higher and no negative revisions [12] - STGW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3][7] - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated expectations [8] - While price targets should not be ignored, they should be approached with skepticism to avoid disappointing returns on investment [10]

Core Viewpoint - InfuSystems Holdings, Inc. (INFU) has seen a 1.8% increase in share price over the past four weeks, closing at $10, with analysts suggesting a potential upside of 40% based on a mean price target of $14 [1] Price Targets - The average price target consists of five estimates ranging from a low of $12.00 to a high of $15.00, with a standard deviation of $1.41, indicating a potential increase of 20% to 50% from the current price level [2] - A low standard deviation suggests a strong agreement among analysts regarding the price targets, which can be a positive indicator for investors [2][9] Analyst Sentiment - Analysts have shown increasing optimism about INFU's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - The Zacks Consensus Estimate for the current year has risen by 13.7% over the past month, with no negative revisions, indicating a favorable outlook for the company [12] Zacks Rank - INFU holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, further supporting the potential for stock price appreciation [13] Conclusion on Price Movement - While the consensus price target may not be entirely reliable, the direction indicated by the price movement appears to be a useful guide for potential investment decisions [14]

Core Viewpoint - Columbus McKinnon (CMCO) shows significant upside potential with a mean price target of $31, indicating a 104.1% upside from the current price of $15.19 [1] Price Targets and Estimates - The average price target for CMCO ranges from a low of $15.00 to a high of $50.00, with a standard deviation of $17.69, suggesting variability in analyst estimates [2] - The lowest estimate indicates a potential decline of 1.3%, while the highest suggests a 229.2% upside [2] - Analysts' consensus on price targets should be approached with caution, as their reliability has been questioned [3][7] Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding CMCO's earnings prospects supports the expectation of stock upside, as indicated by positive earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has increased by 1.6% over the past month, with no negative revisions [12] - CMCO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of potential gains, the direction implied by these targets appears to be a useful guide for further research [14]

Group 1: Stock Performance and Price Targets - Life Time Group Holdings, Inc. (LTH) shares have increased by 0.5% over the past four weeks, closing at $26.18, with a mean price target of $39.23 indicating a potential upside of 49.9% [1] - The average of 13 short-term price targets ranges from a low of $28.00 to a high of $48.00, with a standard deviation of $5.53, suggesting a 7% increase from the current price at the lowest estimate and an 83.4% upside at the highest [2] Group 2: Analyst Consensus and Earnings Estimates - There is strong agreement among analysts regarding LTH's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.1%, with two estimates moving higher and no negative revisions [12] - LTH currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Group 3: Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3] - Price targets set by analysts often reflect overly optimistic views due to business incentives, which can lead to inflated estimates [8] - While a tight clustering of price targets indicates agreement among analysts, it does not guarantee that the stock will reach the average target [9]

Core Viewpoint - Allegro MicroSystems, Inc. (ALGM) shows potential for significant upside, with a mean price target of $38.75 indicating a 33.9% increase from its current price of $28.94 [1] Price Targets and Analyst Consensus - The average price target consists of 12 estimates ranging from $35.00 to $49.00, with a standard deviation of $4.14, suggesting a variability in analyst predictions [2] - The lowest estimate indicates a 20.9% increase, while the highest suggests a 69.3% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about ALGM's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, one estimate has increased, leading to a 7.8% rise in the Zacks Consensus Estimate [12] - ALGM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, as empirical research indicates they rarely predict actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - El Pollo Loco Holdings (LOCO) has shown a significant price increase of 11.1% over the past four weeks, with a mean price target of $14 indicating a potential upside of 35.9% from the current price of $10.3 [1] Price Targets and Analyst Estimates - The mean estimate for LOCO comprises three short-term price targets with a standard deviation of $3.61, suggesting variability in analyst predictions. The lowest estimate is $11.00 (6.8% increase), while the highest is $18.00 (74.8% increase) [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about LOCO's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 6.9%, with two estimates moving higher and no negative revisions [12] - LOCO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While consensus price targets are often sought after, they may not reliably indicate actual stock price movements, and investors should approach them with skepticism [3][10]

Core Viewpoint - Neogen (NEOG) shares have increased by 11.7% in the past four weeks, closing at $6.29, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $8.17, representing a 29.9% upside [1] Price Targets - The average price targets range from a low of $6.50 to a high of $10.00, with a standard deviation of $1.76, indicating variability among analysts [2] - The lowest estimate suggests a 3.3% increase, while the highest estimate indicates a 59% upside [2] Analyst Consensus and Earnings Estimates - Analysts show a strong agreement in revising earnings estimates higher, which historically correlates with stock price movements [4][11] - The Zacks Consensus Estimate for the current year has increased by 50% over the past month, with no negative revisions [12] - NEOG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Group 1 - Rithm (RITM) shares have increased by 1.6% over the past four weeks, closing at $11.07, with a mean price target of $14.14 indicating a potential upside of 27.7% [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $1.11, where the lowest estimate is $12.50 (12.9% increase) and the highest is $16.00 (44.5% increase) [2] - Analysts show strong agreement on RITM's ability to report better earnings, with a positive trend in earnings estimate revisions suggesting potential upside [4][11] Group 2 - The Zacks Consensus Estimate for RITM's current year has increased by 1.2% over the last 30 days, with one estimate moving higher and no negative revisions [12] - RITM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of RITM's potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Apogee Therapeutics Inc. (APGE) has seen a significant stock price increase of 41.4% over the past four weeks, closing at $55.7, with analysts suggesting a potential upside of 69.3% based on a mean price target of $94.3 [1][11]. Price Targets and Analyst Estimates - The mean estimate for APGE comprises 10 short-term price targets with a standard deviation of $16.3, indicating variability among analysts. The lowest estimate suggests a 7.7% increase to $60.00, while the highest estimate predicts a surge of 108.3% to $116.00 [2][9]. - A tight clustering of price targets, represented by a low standard deviation, indicates a high degree of agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings per share (EPS) estimates higher for APGE, which is a positive indicator for potential stock upside. This correlation between earnings estimate revisions and stock price movements is supported by empirical research [4][11]. - Over the past 30 days, one estimate for APGE has increased, leading to a 0.9% rise in the Zacks Consensus Estimate, with no negative revisions noted [12]. Zacks Rank and Investment Potential - APGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, which further supports its potential upside [13]. - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a useful guide for the direction of price movement [14].

Core Viewpoint - Ocular Therapeutix (OCUL) shares have increased by 4% recently, with a mean price target of $21 indicating a potential upside of 82.9% from the current price of $11.48 [1] Price Targets and Analyst Estimates - The mean estimate consists of 12 short-term price targets with a standard deviation of $4.92, suggesting variability in analyst predictions [2] - The lowest estimate of $14.00 indicates a 22% increase, while the highest estimate suggests a 170% surge to $31.00 [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - There is strong agreement among analysts regarding OCUL's ability to report better earnings, which supports the potential for stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 5.4%, with four estimates moving higher and no negative revisions [12] - OCUL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While consensus price targets may not be reliable for predicting the extent of OCUL's gains, they can provide a directional guide for potential price movement [14]